Read by QxMD icon Read

Hematology/oncology and Stem Cell Therapy

Laura Prohaska, Zahra Mahmoudjafari, Leyla Shune, Anurag Singh, Tara Lin, Sunil Abhyankar, Siddhartha Ganguly, Dennis Grauer, Joseph McGuirk, Lisa Clough
OBJECTIVE/BACKGROUND: Clostridium difficile infection (CDI) is a potential complication during hematopoietic stem cell transplantation (HSCT), and no specific recommendations exist regarding treatment of CDI in allogeneic SCT patients. Use of metronidazole and oral vancomycin has been associated with clinical failure. Fidaxomicin has previously been found noninferior to the use of oral vancomycin for the treatment of CDI, and no studies have compared the use of oral vancomycin with fidaxomicin for the treatment of CDI in allogeneic SCT...
June 18, 2018: Hematology/oncology and Stem Cell Therapy
Ahmad Alshomar, Riad El Fakih
Lymphoblastic lymphomas (LBLs) are neoplasms of precursor B and T cells; they are considered in the same spectrum as precursor B and T cell acute lymphoblastic leukemia (ALL). The World Health Organization classification classifies both LBL and ALL as one disease entity. While chromosome abnormalities are well defined with all of their therapeutic and prognostic implications in ALL, these are not well studied in LBL. Here, we describe a case of Philadelphia chromosome-positive LBL and review the available literature regarding this entity...
June 15, 2018: Hematology/oncology and Stem Cell Therapy
Sarbajit Mukherjee, Sami Ibrahimi, Teresa Scordino, Mohamad Cherry
No abstract text is available yet for this article.
June 15, 2018: Hematology/oncology and Stem Cell Therapy
Yacoub A Yousef, Maysa Al-Hussaini, Rashed Nazzal, Ghadeer Abdeen, Ibrahim Alnawaiseh, Khaleel Alrawashdeh
OBJECTIVE/BACKGROUND: Intra ocular Rosai-Dorfman disease (RDD) is an extremely rare disease. We are reporting the first case of RDD presenting as ciliary body mass mimicking ciliary body melanoma, and we are reviewing the English literature reporting on cases of RDD presented with intraocular disease. METHODS: An 18-year-old lady presented with loss of vision in the right eye, and was found to have intraocular mass lesion. She was diagnosed clinically and radiologically as a case of ciliary body melanoma associated with total retinal detachment...
June 15, 2018: Hematology/oncology and Stem Cell Therapy
Burak Furkan Demir, Aysenur Karahan Meteris, Gokhan Yirgin, Mustafa Comoglu, Bilal Katipoglu, Nisbet Yılmaz, Ihsan Ates
No abstract text is available yet for this article.
June 14, 2018: Hematology/oncology and Stem Cell Therapy
Hikmat Abdel-Razeq
Despite the recent advances in breast cancer early detection and awareness, a significant portion of patients present with an advanced-stage disease and more patients will progress to stage IV despite adequate treatment of their initial early-stage disease. Hormone receptor (HR)-positive, Human Epidermal Growth Factor Receptor-2 (HER2)-negative subtype is the commonest among all breast cancer subtypes. The management of the advanced-stage disease of this subtype has evolved significantly over the past few years...
May 19, 2018: Hematology/oncology and Stem Cell Therapy
Sunil Pasricha, Neha Singh, Ajit Panaych, Anurag Mehta
No abstract text is available yet for this article.
May 19, 2018: Hematology/oncology and Stem Cell Therapy
Showkat Ahmad Bhat, Manzoor Ur Rahman Mir, Sabhiya Majid, Tehseen Hassan, Muneeb U Rehman, Sonallah Kuchy
OBJECTIVE/BACKGROUND: Posttranslational modification of proteins, including glycosylation, is known to differ between normal and tumor cells. Altered glycosyltransferase levels have been observed in tumor tissues and their role in tumor metastasis and invasion has been implicated. In this study the role of altered glycosyltransferase messenger RNA (mRNA) levels in serum of gastric cancer patients as early markers of gastric cancer was evaluated. METHODS: In this case control study the expression profile of ppGalNAc-T6, GlcNAcT-V, ST3Gal I, ST3 Gal IV, and ST6GalNAc-I in normal healthy control and gastric cancer patients was compared...
April 27, 2018: Hematology/oncology and Stem Cell Therapy
Moaath Mustafa Ali, Donna M Corrigan, Lisa A Rybicki, Melissa A Yurch, Kelly Cherni, Hien Liu, Robert Dean, Betty Hamilton, Brad Pohlman, Steven Andresen, Matt Kalaycio, Brian J Bolwell, Navneet S Majhail, Ronald Sobecks
No abstract text is available yet for this article.
April 24, 2018: Hematology/oncology and Stem Cell Therapy
Sanjay de Mel, Yunxin Chen, Adeline Lin, Teck Guan Soh, Melissa Ooi, Eng Soo Yap, Lara Kristina Sioco Donato, Nurul Aidah Abdul Halim, Joanna Mah, Karen Lim, Li Mei Poon, Belinda Tan, Yelly, Hui Li Lim, Liang Piu Koh, Bee Choo Tai, Zhaojin Chen, Wee Joo Chng, Satish Kumar Gopalakrishnan, Lip Kun Tan
BACKGROUND: High dose Cyclophosphamide (Cy) and Vinorelbine Cyclophosphamide (Vino-Cy) are stem cell (SC) mobilisation options for patients with multiple myeloma (MM). We present a comparison of mobilisation outcomes using these regimens. PATIENTS AND METHODS: Vino-Cy patients received Vinorelbine 25 mg/m2 on day 1, cyclophosphamide 1500 mg/m2 on day 2, and pegylated GCSF on day 4 or GCSF 10 mcg/kg/day from day 4 onwards. Cy patients were given cyclophosphamide 4000 mg/m2 on day 1 and GCSF10 mcg/kg/day from day 5 onwards...
April 23, 2018: Hematology/oncology and Stem Cell Therapy
Nour AlMozain, Tarek Owaidah
No abstract text is available yet for this article.
June 2018: Hematology/oncology and Stem Cell Therapy
Hayder Saeed, Swati Yalamanchi, Meng Liu, Emily Van Meter, Zartash Gul, Gregory Monohan, Dianna Howard, Gerhard C Hildebrandt, Roger Herzig
OBJECTIVES: Allogeneic hematopoietic stem cell transplant (HCT) continues to evolve with the treatment in higher risk patient population. This practice mandates stringent update and validation of risk stratification prior to undergoing such a complex and potentially fatal procedure. We examined the adoption of the new comorbidity index (HCT-CI/Age) proposed by the Seattle group after the addition of age variable and compared it to the pre-transplant assessment of mortality (PAM) that already incorporates age as part of its evaluation criteria...
June 2018: Hematology/oncology and Stem Cell Therapy
Mohamed A Kharfan-Dabaja, Nour Moukalled, Tea Reljic, Jessica El-Asmar, Ambuj Kumar
Despite availability of new and more effective therapies for chronic lymphocytic leukemia, presently this disease remains incurable unless eligible patients are offered an allogeneic hematopoietic cell transplant. Recent published clinical practice recommendations on behalf of the American Society for Blood and Marrow Transplantation relegated the role of for allogeneic hematopoietic cell transplantation to later stages of the disease. To our knowledge, no randomized controlled trial has been performed to date comparing myeloablative versus reduced intensity conditioning regimens in chronic lymphocytic leukemia patients eligible for the procedure...
June 2018: Hematology/oncology and Stem Cell Therapy
Rasha Abdel-Raouf Afifi, Dina Kamal, Riham El Sayed, Sherif M M Ekladious, Gehan H Shaheen, Sherif M Yousry, Rania Elsayed Hussein
OBJECTIVES: To detect the frequency of CD209 A>G polymorphism in sickle cell disease (SCD) Egyptian patients and to evaluate the use of CD209 A>G polymorphism as a genetic predictor of SCD clinical heterogeneity. METHODS: A total of 100 Egyptian children with SCD and 100 Egyptian controls were tested for CD209 A>G polymorphism and were followed up prospectively between June 2012 and December 2014. RESULTS: Comparison of CD209 A>G polymorphism among cases and controls did not show statistically significant difference (p = ...
June 2018: Hematology/oncology and Stem Cell Therapy
Dushyant Kumar, Anurag Mehta, Manoj Kumar Panigrahi, Sukanta Nath, Kandarpa Kumar Saikia
OBJECTIVE/BACKGROUND: In the absence of high-risk cytogenetic, DNMT3A (DNA Methyltransferase 3a) mutation status has an impact on outcome in the presence of FLT3 (FMS-like Tyrosine Kinase3) and/or NPM1 (Nucleophosmin). In this study, we focus on the features and effect of DNMT3A (R882) mutation in acute myeloid leukemia (AML) in the presence or absence of NPM1 and FLT3 mutations. METHODS: A total of 174 cytogenetically normal (CN)-AML cases were analyzed for NPM1, FLT3, and DNMT3A mutations...
June 2018: Hematology/oncology and Stem Cell Therapy
Moussab Damlaj, Gamal Gmati, Ghulam Syed, Tabrez Pasha, Hend Salama, Osama Ali, Khadega A Abuelgasim, Mohsen Al-Zahrani, Ahmad Al Askar, Ayman Alhejazi
No abstract text is available yet for this article.
June 2018: Hematology/oncology and Stem Cell Therapy
Vitaliy Mykytiv, Fiz Campoy Garcia
We present a rare case of anaemia secondary to bone marrow infiltration by oxalate crystals and renal failure in a patient diagnosed with primary hyperoxaluria. In our case, the anaemia was recovered after the double liver and kidney transplantation, the latter was performed on two occasions after the failure of the first graft.
June 2018: Hematology/oncology and Stem Cell Therapy
Lindsay Hammons, Ruta Brazauskas, Marcelo Pasquini, Mehdi Hamadani, Parameswaran Hari, Anita D'Souza
OBJECTIVE/BACKGROUND: To assess abnormalities found on CD138-enriched fluorescent in situ hybridization (FISH) studies on pre-treatment bone marrow in systemic amyloid light-chain amyloidosis (AL) and correlate findings between these abnormalities with organ involvement and 1-year survival. METHODS: We reviewed 107 patients with systemic AL to identify the impact of a diagnostic FISH study done on plasma cell-enriched bone marrow in our institution between January 2010 and January 2015; 77 had pre-treatment testing performed...
June 2018: Hematology/oncology and Stem Cell Therapy
Mahmoud Alhosiny Fayed, Hesham El-Sayed Abdel-Hady, Mona Mohammed Hafez, Osama Saad Salama, Youssef Abdelhalim Al-Tonbary
BACKGROUND: The increased survival rate of thalassemic patients has led to unmasking of management related complications which were infrequently encountered. OBJECTIVE: Study the increased coagulation and platelet activation in children with β-thalassemia, to analyze the factors that lead to such hypercoagulable state and to study pulmonary hypertension (PH) in conjunction with platelet activation and hypercoagulable state in children with β-thalassemia. METHODS: 36 Egyptian children with β-thalassemia with a mean age of 9...
June 2018: Hematology/oncology and Stem Cell Therapy
Iman Abou Dalle, Samer Nassif, Ali Bazarbachi
Pathologic increase in bone marrow reticulin fibrosis can be present in many malignant hematopoietic diseases. In acute leukemia, one-third of patients have some degree of marrow reticulin fibrosis at presentation, which is thought to be related to cytokine release from blasts. Marrow fibrosis is particularly common in acute megakaryoblastic leukemia, while this change is rarely seen in acute promyelocytic leukemia. Six case reports of acute promyelocytic leukemia with marrow reticulin fibrosis have been described so far in the literature...
June 2018: Hematology/oncology and Stem Cell Therapy
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"